Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly, If baseless claims weren't directed against my initial post I would have never posted here again.
I can change the stock price, I didn't realize I had that much power.
So then tell us all where the similarities are. The CEO of ENZC must surely have backed up his specious claims.
Give me a link to their studies that show the structural similarities between HIV and COVID-19.
Because I am invested in CYDY is why I know the science. I've spent a few thousand hours reading medical papers on immunomodulation, autoimmunity and the coronavirus. Like I said flip it and make some money, hold it and you will be weeping.
ps. The toxicology studies say nothing about it's efficacy.
It was created for HIV so that would mean that HIV and COVID-19 have the same structure. I wonder why scientists the world over haven't noticed this. That would mean it actually docks to CCR5 not ACE2 so the CCR5 blockers will end this pandemic right now.
That actually may cause a bump up because with penny flippers in the end greed and stupidity win out over intelligent investing.
Because they haven't dumped enough shares to bring it down to .0001 yet.
Do people who invest in biopharmas know nothing about what they're investing in? Viral antibodies are quite specific to each type of virus. Why would you expect an HIV antibody to work for a coronavirus. So now we have a non-working antibody combined with a pro-inflammatory in a disease in which inflammation is what's killing people.
If you want to flip penny stocks, go for it. Don't try to justify it with bogus science.
Karen did not blow it. How many millions of dollars was her share of the cut?
1.6 billion shares dumped by the company in less than a year is always the sign of a winner.
The science behind ITV-1 hasn't changed. It was proposed for HIV exactly because it ramps up the immune response. With the overwhelming viral action of HIV simply ramping up immune response doesn't stand a chance. Which is obvious since it has no approvals anywhere.
If you can't see that ramping up the immune response in a patient with an already out of control immune response is a bad idea then common sense is not your forte. Of course maybe it's just that you are a penny stock pumper trying to dupe the gullible.
I would however suggest anyone who is thinking of investing do some due diligence on this company and it's officers. I haven't but the pattern is so obvious I don't need too.
Be happy you're on the upside of the pump. Just don't wait to sell until after they do a share offer.
Someone just asked me about this garbage elsewhere.
Pure pump and dump. The mechanism of action for ITV-1 is to "resulting in an increase in the number of the following lymphocyte populations: CD3, CD16, CD56, CD45, CD4, CD19 and the correlation CD4 / CD8.".
The last thing you want in inflammatory or autoimmune diseases is to increase inflammatory macrophages. In fact ITV-1 would make the situation worse.
It's a sure thing that Enzolytics picked up a failed drug to tout for Covid just for the ability to dump more shares on the market. I know they at one time were offering mobile coating franchises. What other businesses have they trued to push, solar, marijuana, electric vehicles are some of the popular ones.
https://www.researchgate.net/publication/320011459_ITV-1_Irreversible_Pepsin_Fraction_Clinical_Data_from_Bulgarian_Phase_III_Clinical_Trial
If the problem with HIV combo BLA was that the tests were denied by the FDA because they lacked certification then problem solved, new tests will not have to be done.
Does HGEN have 65 potential indications?
402 - 257 = 145
145/402 = .3606
https://www.fiercebiotech.com/biotech/humanigen-links-drug-to-improvements-severe-covid-19-patients
I don't have to read it. The title says it all "when promising", not "when statistically significant".
Which doesn't make it any less true. Read it and weep.
It does if you can't follow logic.
HGEN's Falsehood
Let's reverse engineer HGEN's reverse engineered statement of 37% improvement for lenzilumab. How did HGEN come up with 37%? They divided the initial recovery target for patients of 257 by the new target of 402. That is faulty methodology. The trial was not going to hit stat sig at 257 so an increase greater than actual efficacy was needed to try and hit stat sig.
We know 29% improvement was needed to hit the minimum statistical value to not shut down the trial due to futility. That was most likely set at higher than p= .05 with an eye towards it achieving p= .05 with the increased number of patients at full enrollment. If lenzilumab had hit that p= threshold than no additional patients would be needed. That 37% additional patients were needed to achieve stat sig shows efficacy must be below 29%.
If you believed HGEN's explanation in their PR then you've been had.
Fake as hell. All FDA FOIA requests would be listed here. The only ones are for EINDs. You could always break out the crayons.
https://search.usa.gov/search?query=cytodyn&affiliate=fda1
I would think that vaccination would increase the number of CCR5 receptors making it more difficult for leronlimab to cover all receptors. In HIV the closer to 100% coverage the better the success rate. In cancer or other diseases involving cytokine blockade 100% is ideal but you'll see positive effects at lesser coverage.
False headline
The problem I could see with that approach is there was no baseline so no way to see progression. The second problem is that the number of patients is too small to do a comparative study. If none ot a very small number of patients had NASH you could infer it was due to leronlimab but that won't impress the FDA.
Things that make you wonder. Only 5 aviptadil patients were on ECMO, yet 13 control patients were. Of course that wouldn't skew the results. The results are completely untrustworthy.
PFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 VACCINE CANDIDATE, MEETING ALL PRIMARY EFFICACY ENDPOINTS
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
Our trial is for severe/critical and that's what it will be approved for. Getting people off of ventilators is nice but the point is to treat them so they never are put on a vent. In the short term mild/moderate is an afterthought because we initially won't have enough production to meet demand. Then we'll also have demand from longhaulers and HIV.
Ohm's Law of CYDY.
leronlimab x number of indications = $$$$$$$$$$$$$ and many lives saved
Guillain Barre on the Master Disease List. I'm looking forward to the results of the longhaulers trial.
What they're seeing in that study is antibodies against Interferon alpha and Interferon omega having a negative effect. Those interferons induce virus killing cells so with antibodies shutting them down the body is not killing off the virus effectively. So you have proliferation of the virus and nothing shutting down the cytokine storm.
Leronlimab downregulates Interferon gamma which is responsible along with IL-6 in macrophage recruitment that causes inflammation along with other inflammatory cytokines, shutting down the cytokine storm. It also boosts CD-8+ T-cells to fight the virus. By downregulating neuropilin-1 it also blocks a secondary COVID-19 entry site. Leronlimab also most likely works as an antiviral by disruption of the mTOR-1 pathway.
"Don’t have a clue as how to treat him. - ROCKLEO"
Has Dexamethasone been tried for the sepsis?
I guess we should sell all of our Cytodyn. "Dr." Stengler has the cure for everything (except for charlatanism).
Gillian Barre is on the Master Disease List.
Leronlimab - Disease List (currently 65)
(updated 7-17-2020)
An incomplete list of potential treatment targets for leronlimab.
Acute Respiratory Distress Syndrome
Allergies (anaphylactic shock)
Alopecia Areata
Alzheimer's
Amyotrophic Lateral Sclerosis
Anthrax
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Castleman Disease
Coeliac Disease
Chronic Fatigue Syndrome
Chronic Kidney Disease (underlying pathologies)
COPD
COVID-19 (and other coronaviruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy (possibly other muscular dystrophies also)
Emphysema
Endometriosis
Fibromyalgia
Gout
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lewy Body Dementia
Lupus
Lyme Disease
Marshall’s syndrome (PFAPA)
Miller Fisher Syndrome
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Osteomyelitis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Pulmonary Arterial Hypertension
Pulmonary Fibrosis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sepsis
Sickle Cell Disease (anti-inflammatory and anti-hypercoagulability effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis
Which of those drugs treats severe/critical patients? Such obvious misinformation.
No theories needed, that's the way flippers work.
You're spot on. Thank you for answering, one post a day is not conducive to responding. Unfortunately for us Dr. Patterson cannot check this out or my hypothesis about mTOR/4E-BP1 pathway dysregulating elF4E, locking the virus endcap and stopping virus RNA separation.